Loading...
XNAS
NVNO
Market cap7mUSD
Dec 05, Last price  
0.35USD
1D
-8.87%
1Q
-54.25%
IPO
-96.55%
Name

enVVeno Medical Corp

Chart & Performance

D1W1MN
XNAS:NVNO chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
93.59%
Rev. gr., 5y
-55.86%
Revenues
0k
236,5000785,912422,111186,55231,24300000
Net income
-22m
L-7.22%
-1,018,152-1,604,013-3,387,490-7,791,469-13,042,709-7,625,397-8,919,940-16,196,413-24,304,000-23,516,000-21,819,000
CFO
-17m
L-10.71%
0-2,019,463-3,084,657-4,202,240-6,355,838-5,896,400-7,677,210-11,845,846-15,619,000-18,858,000-16,838,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
IPO date
May 31, 2018
Employees
19
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT